Asceneuron SA’s Post

View organization page for Asceneuron SA, graphic

2,865 followers

View organization page for Asceneuron SA, graphic

2,865 followers

#Asceneuron_sa announces $100 million oversubscribed Series C financing! Today we announce that we have successfully secured a Series C financing, led by Novo Holdings with new investment from EQT Group Life Sciences, OrbiMed and SR One Capital Management Capital Management, alongside participation from existing investors M Ventures , Sofinnova Partners, GSK Equities Investment Limited and Johnson & Johnson Innovation JJDC Inc. The funds will be used to advance our lead asset #ASN51, an oral small molecule drug designed to inhibit #OGA into Phase 2 clinical development for the treatment of Alzheimer’s disease. Click here https://lnkd.in/d278vevG to read the press release and discover more about Asceneuron’s groundbreaking clinical pipeline of O-GlcNAcase inhibitors for the treatment of #neurodegenerative diseases. #neurodegeneration #ALS #alzheimers #parkinson #dementia #financing

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics